Literature DB >> 12755665

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

Murad Atmaca1, Murat Kuloglu, Ertan Tezcan, Bilal Ustundag.   

Abstract

BACKGROUND: Weight gain is a common adverse effect associated with the use of most antipsychotic drugs. Leptin has been reported to be associated with antipsychotic-induced weight gain. Previous studies have demonstrated a relationship between the atypical antipsychotics clozapine and olanzapine and serum leptin levels. We planned to comparatively investigate the effects of the atypical antipsychotics quetiapine, olanzapine, risperidone, and clozapine on leptin and triglyceride levels and weight gain.
METHOD: The study population comprised 56 patients with DSM-IV schizophrenia, who were divided into 4 treatment groups: quetiapine (N = 14), olanzapine (N = 14), risperidone (N = 14), or clozapine (N = 14) monotherapy, and a control group of 11 patients receiving no psychopharmacologic treatment. The patients were evaluated at baseline and at the sixth week according to the Positive and Negative Syndrome Scale (PANSS), body mass index (BMI), weight, and fasting serum leptin and triglyceride levels. Data were gathered in 2001 and 2002.
RESULTS: Olanzapine and clozapine caused a marked increase in weight and serum triglyceride and leptin levels, though increases in these variables were modest in the patients receiving quetiapine and minimal in those receiving risperidone. There were positive correlations between serum leptin levels and BMI and triglyceride levels. Clinical efficacy, as indicated by decrease in total PANSS scores, was associated with leptin levels in all atypical antipsychotic groups.
CONCLUSION: Our results suggest that leptin may be associated with olanzapine- and clozapine-induced weight gain and that quetiapine appears to have modest influence and risperidone appears to have minimal influence on leptin and triglyceride levels and weight gain compared with olanzapine and clozapine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12755665     DOI: 10.4088/jcp.v64n0516

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  43 in total

1.  A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics.

Authors:  Benjamin U Nwosu; Bruce Meltzer; Louise Maranda; Carol Ciccarelli; Daniel Reynolds; Laura Curtis; Jean King; Jean A Frazier; Mary M Lee
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

2.  Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.

Authors:  R Coccurello; A Caprioli; O Ghirardi; R Conti; B Ciani; S Daniele; A Bartolomucci; A Moles
Journal:  Psychopharmacology (Berl)       Date:  2006-05-13       Impact factor: 4.530

3.  A crossover study on lipid and weight changes associated with olanzapine and risperidone.

Authors:  Kuan-Pin Su; Po-Lun Wu; Carmine M Pariante
Journal:  Psychopharmacology (Berl)       Date:  2005-10-21       Impact factor: 4.530

4.  A prospective study of serum ghrelin levels in patients treated with clozapine.

Authors:  F M Theisen; S Gebhardt; T Brömel; B Otto; W Heldwein; M Heinzel-Gutenbrunner; J-C Krieg; H Remschmidt; M Tschöp; J Hebebrand
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

Review 5.  Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Authors:  Leslie Citrome; Richard I G Holt; Daniel J Walker; Vicki Poole Hoffmann
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 6.  Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia.

Authors:  Hu Yan; Jin-Dong Chen; Xiao-Yan Zheng
Journal:  Psychopharmacology (Berl)       Date:  2013-07-06       Impact factor: 4.530

7.  Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry Analysis.

Authors:  Yoshinori Takeuchi; Kazuhiro Kajiyama; Chieko Ishiguro; Yoshiaki Uyama
Journal:  Drug Saf       Date:  2015-07       Impact factor: 5.606

Review 8.  Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.

Authors:  Hua Jin; Jonathan M Meyer; Sunder Mudaliar; Dilip V Jeste
Journal:  Schizophr Res       Date:  2008-01-18       Impact factor: 4.939

9.  Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment.

Authors:  Ric M Procyshyn; Kishor M Wasan; Allen E Thornton; Alasdair M Barr; Eric Y H Chen; Edith Pomarol-Clotet; Emmanuel Stip; Richard Williams; G William Macewan; C Laird Birmingham; William G Honer
Journal:  J Psychiatry Neurosci       Date:  2007-09       Impact factor: 6.186

10.  The relationships of leptin, adiponectin levels and paraoxonase activity with metabolic and cardiovascular risk factors in females treated with psychiatric drugs.

Authors:  Aliye Ozenoglu; Huriye Balci; Serdal Ugurlu; Erkan Caglar; Hafize Uzun; Cihat Sarkis; Can Gunay; Engin Eker E
Journal:  Clinics (Sao Paulo)       Date:  2008-10       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.